Early use of glycoprotein IIb/IIIa inhibitors in the ED treatment of non-ST-segment elevation acute coronary syndromes: a local quality improvement initiative.

[1]  E. Fody,et al.  The Erlanger chest pain evaluation protocol: a one-year experience with serial 12-lead ECG monitoring, two-hour delta serum marker measurements, and selective nuclear stress testing to identify and exclude acute coronary syndromes. , 2002, Annals of emergency medicine.

[2]  Robert H Christenson,et al.  Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[3]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[4]  Robert Parrish,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.

[5]  E. Peterson,et al.  Early use of glycoprotein 2b3a inhibitors and outcomes in non-ST elevation MI: observations from the NRMI-4 , 2002 .

[6]  R. Grol.  Improving the quality of medical care: building bridges among professional pride, payer profit, and patient satisfaction. , 2001, JAMA.

[7]  F. Fesmire,et al.  Selective dual nuclear scanning in low-risk patients with chest pain to reliably identify and exclude acute coronary syndromes. , 2001, Annals of emergency medicine.

[8]  H. Krumholz,et al.  A Qualitative Study of Increasing β-Blocker Use After Myocardial Infarction: Why Do Some Hospitals Succeed? , 2001 .

[9]  W. Rogers,et al.  Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. , 2000, Journal of the American College of Cardiology.

[10]  K. Eagle,et al.  Quality improvement initiative and its impact on the management of patients with acute myocardial infarction. , 2000, Archives of internal medicine.

[11]  F. Fesmire.  Which chest pain patients potentially benefit from continuous 12-lead ST-segment monitoring with automated serial ECG? , 2000, The American journal of emergency medicine.

[12]  R. Giugliano,et al.  Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. , 2000, The American journal of cardiology.

[13]  F. Fesmire.  A rapid protocol to identify and exclude acute myocardial infarction: continuous 12-lead ECG monitoring with 2-hour delta CK-MB. , 2000, The American journal of emergency medicine.

[14]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .

[15]  M. Radford,et al.  What's Happening in Quality Improvement at the Local Hospital: A State Wide Study From the Cooperative Cardiovascular Project , 2000, American journal of medical quality : the official journal of the American College of Medical Quality.

[16]  W. French.  Trends in acute myocardial infarction management: use of the National Registry ofMyocardial Infarction in quality improvement. , 2000, The American journal of cardiology.

[17]  A. Gawlinski,et al.  Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. , 2000, The American journal of cardiology.

[18]  F. Fesmire,et al.  Delta CK-MB outperforms delta troponin I at 2 hours during the ED rule out of acute myocardial infarction. , 2000, The American journal of emergency medicine.

[19]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. , 1999, Circulation.

[20]  N. Every,et al.  A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project. , 1999, Journal of the American College of Cardiology.

[21]  E. Ellerbeck,et al.  Quality Improvement at the National Level , 1998, Evaluation & the health professions.

[22]  F. Fesmire,et al.  Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6ng/ml. , 1998, American heart journal.

[23]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[24]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[25]  S B Soumerai,et al.  Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. , 1998, JAMA.

[26]  D. Berman,et al.  Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. , 1998, Circulation.

[27]  F. Fesmire,et al.  Usefulness of automated serial 12-lead ECG monitoring during the initial emergency department evaluation of patients with chest pain. , 1998, Annals of emergency medicine.

[28]  C. Heeschen,et al.  Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. , 1997, The New England journal of medicine.

[29]  W. Gibler,et al.  Serial creatine kinase-MB results are a sensitive indicator of acute myocardial infarction in chest pain patients with nondiagnostic electrocardiograms: the second Emergency Medicine Cardiac Research Group Study. , 1997, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[30]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[31]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[32]  F. Harrell,et al.  Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia , 1996 .

[33]  D Wybenga,et al.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. , 1996, The New England journal of medicine.

[34]  R. D. de Winter,et al.  Prognostic value of troponin T, myoglobin, and CK-MB mass in patients presenting with chest pain without acute myocardial infarction. , 1996, Heart.

[35]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[36]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[37]  Kendall Gh.  Improving the quality of medical care. , 1989 .

[38]  R J Prineas,et al.  International diagnostic criteria for acute myocardial infarction and acute stroke. , 1984, American heart journal.